A man in his 60s came to the clinic with a history of arterial blockage and previous heart attack. He had been treated using chelation therapy 5 years ago, just after the heart attack, with chelation therapy and benefited at the time. The man was a non-smoker, who exercised daily but was noticing significant shortness of breath with activity in the last 6 months.
A cardiac MRI indicated poor blood flow and that the patient was at high risk for a future cardiac event. His previous history including mercury fillings (now removed), and occupational exposure to lead.
A treatment plan was developed for the patient to continue chelation therapy, using EDTA, and to add IV phosphatidylcholine. Phosphatidylcholine is a lipid naturally found in our cell membranes. As we age and are exposed to toxins in our food and the environment, the amount of phospholipid in our membranes decreases. Research how shown that phosphatidylcholine can reduce serum cholesterol up to 30%, increase HDL levels, and improve the LDL/HDL ratio. In addition the treatments have been shown to decrease lipid oxidation, decrease plaque formation and decrease platelet aggregation. Human trials have also reported a decrease in angina attacks after treatment with IV phosphatidylcholine.
It was recommended the patient receive a series of 30 IV treatments of a combination of IV EDTA and Phosphatidylcholine, as IV phosphatidylcholine has been shown to get the best results with a series of treatments. After 15 treatments the patient has already reported a significant improvement and was no longer experiencing shortness of breath with no recent chest pain. The patient will complete the series or recommended IVs and then continue with maintenance therapy.
